P. Bombaron

5.9k total citations
24 papers, 189 citations indexed

About

P. Bombaron is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, P. Bombaron has authored 24 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in P. Bombaron's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Multiple and Secondary Primary Cancers (5 papers). P. Bombaron is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Multiple and Secondary Primary Cancers (5 papers). P. Bombaron collaborates with scholars based in France, United Kingdom and Belgium. P. Bombaron's co-authors include P. Fournel, M. Pérol, G. Robinet, Pierre Jean Souquet, L. Gérinière, H. Bérard, H. Léna, L. Falchero, Jean-Luc Breton and F. Philip‐Joet and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.

In The Last Decade

P. Bombaron

23 papers receiving 187 citations

Peers

P. Bombaron
Masanari Hamaguchi Japan
Hamzeh Albaba Canada
Alice Baggi Italy
Sherif Raouf United Kingdom
Kinnosuke Matsumoto Japan
Guillermo González Mexico
Marc Cucurull Spain
Salvador Villà Freixa Spain
Kim Norris United States
C. Clary France
Masanari Hamaguchi Japan
P. Bombaron
Citations per year, relative to P. Bombaron P. Bombaron (= 1×) peers Masanari Hamaguchi

Countries citing papers authored by P. Bombaron

Since Specialization
Citations

This map shows the geographic impact of P. Bombaron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Bombaron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Bombaron more than expected).

Fields of papers citing papers by P. Bombaron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Bombaron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Bombaron. The network helps show where P. Bombaron may publish in the future.

Co-authorship network of co-authors of P. Bombaron

This figure shows the co-authorship network connecting the top 25 collaborators of P. Bombaron. A scholar is included among the top collaborators of P. Bombaron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Bombaron. P. Bombaron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barlési, Fabrice, A. Dixmier, D. Debieuvre, et al.. (2025). Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer. OncoImmunology. 14(1). 2492932–2492932. 1 indexed citations
2.
Mascaux, Céline, M. Zysman, Aurélie Swalduz, et al.. (2022). 37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer. Annals of Oncology. 33. S49–S50. 5 indexed citations
3.
Barlési, Fabrice, A. Dixmier, D. Debieuvre, et al.. (2019). Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study. Annals of Oncology. 30. v613–v613. 1 indexed citations
4.
Pérol, M., A. Dixmier, Fabrice Barlési, et al.. (2019). Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study. Annals of Oncology. 30. ii48–ii48. 3 indexed citations
5.
Dixmier, A., D. Debieuvre, J.B. Auliac, et al.. (2018). EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients. Annals of Oncology. 29. viii532–viii532. 1 indexed citations
6.
Grivaux, M, P. Bombaron, Bernard Asselain, et al.. (2012). Étude KBP-2010-CPHG : description de 7414 nouveaux cas de cancer bronchopulmonaire primitif (CBP) pris en charge dans les hôpitaux généraux en 2010. Revue des Maladies Respiratoires. 29. A26–A26. 1 indexed citations
7.
8.
Bombaron, P., et al.. (2010). Paralysie du nerf récurrent au cours d’une maladie de Lyme : à propos de deux observations. La Revue de Médecine Interne. 31(3). 229–231. 5 indexed citations
9.
10.
Cortot, Alexis B., L. Gérinière, G. Robinet, et al.. (2006). Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Annals of Oncology. 17(9). 1412–1417. 35 indexed citations
11.
Thomas, P., G. Robinet, S. Gouva, et al.. (2005). Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer. Lung Cancer. 51(1). 105–114. 19 indexed citations
12.
Grivaux, M, P. Bombaron, François Lebas, et al.. (2004). Lung cancer among women in France.. Lung Cancer. 45(3). 279–287. 19 indexed citations
13.
Girard, Philippe, et al.. (2004). Management of elderly lung cancer patients in France: A national prospective survey by the French Intergroup of thoracic Oncology (IFCT). Journal of Clinical Oncology. 22(14_suppl). 8163–8163. 6 indexed citations
14.
Lebitasy, Marie-Paule, Isabelle Monnet, A Depierre, et al.. (2004). Management of elderly lung cancer patients in France: A national prospective survey by the French Intergroup of thoracic Oncology (IFCT). Journal of Clinical Oncology. 22(14_suppl). 8163–8163. 7 indexed citations
15.
Bombaron, P., R Riou, P. Fournel, et al.. (2002). Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer. 35(1). 1–7. 28 indexed citations
16.
17.
Khouatra, C., Jérôme Honnorat, P. Bombaron, et al.. (1997). Pseudo-occlusion intestinale et neuronopathie sensitive paranéoplasiques révélatrices d'un cancer bronchique à petites cellules. La Revue de Médecine Interne. 18(8). 652–656. 7 indexed citations
18.
19.
Souquet, P.-J., et al.. (1996). [Spontaneous hydro-pneumothorax disclosing malignant mesothelioma. Apropos of 2 cases].. PubMed. 52(1). 42–4.
20.
Bombaron, P., et al.. (1994). [Recurrent hemothorax due to pleural endometriosis].. PubMed. 11(3). 289–91. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masanari Hamaguchi Breakdown of academic impact, for papers by Hamzeh Albaba Breakdown of academic impact, for papers by Alice Baggi Breakdown of academic impact, for papers by Sherif Raouf Breakdown of academic impact, for papers by Kinnosuke Matsumoto Breakdown of academic impact, for papers by Guillermo González Breakdown of academic impact, for papers by Marc Cucurull Breakdown of academic impact, for papers by Salvador Villà Freixa Breakdown of academic impact, for papers by Kim Norris Breakdown of academic impact, for papers by C. Clary
Rankless by CCL
2026